For example, the combination of a histone deacetylase inhibitor (HDACi) with nanoparticle albumin-bound paclitaxel is part of the metastatic clinical trial to treat HER2-negative IBC [3,38]. This evidence concerns the gene ALB and inflammatory breast carcinoma.